In fact, detection of EGFR amplification or mutations (such as the common vIII deletion or point mutations) is associated with an increase in the aggressiveness of these gliomas, even if the histology corresponds to a grade III tumor [20]. This evidence concerns the gene EGFR and central nervous system cancer.